A private equity group based in the Eastern US has around $800 million in total assets under management, 30% of which are dedicated to the life sciences space. The firm is currently looking for new opportunities within the life science sector, and while they have no set time frame to make an allocation, they would invest in a company within the next six months if a compelling opportunity were uncovered.
The firm is most interested in the medtech space, specifically in firms developing medical devices. The PE only invests in firms that have products that are on the market, and prefers that they have $2-20 million in EBITDA and $10-100 million in revenue. The firm typically makes investments of $2-60 million in the form of subordinated uni-tranche debt. The firm will consider both private as well as smaller public companies.
Next Phase Newsletter 
Leave a comment